PAIOF Stock - Paion AG
Unlock GoAI Insights for PAIOF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $33.25M | $7.13M | $19.66M | $8.00M | $2.77M |
| Gross Profit | $31.29M | $4.05M | $19.66M | $8.00M | $2.77M |
| Gross Margin | 94.1% | 56.8% | 100.0% | 100.0% | 100.0% |
| Operating Income | $1.50M | $-22,079,000 | $1.58M | $-9,326,000 | $-12,455,000 |
| Net Income | $-579,000 | $-21,786,000 | $2.22M | $-7,016,000 | $-9,939,000 |
| Net Margin | -1.7% | -305.6% | 11.3% | -87.7% | -359.3% |
| EPS | $-0.08 | $-3.11 | $0.30 | $-1.08 | $-1.56 |
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
Visit WebsiteEarnings History & Surprises
PAIOFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Jun 2, 2025 | — | — | — | — |
Q2 2025 | May 28, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Nov 4, 2024 | — | — | — | — |
Q3 2024 | Sep 26, 2024 | — | — | — | — |
Q2 2024 | May 15, 2024 | — | — | — | — |
Q1 2024 | Mar 28, 2024 | — | — | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.68 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.73 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-1.55 | — | — |
Q4 2022 | Nov 15, 2022 | — | $-1.02 | — | — |
Q3 2022 | Aug 31, 2022 | — | $-0.56 | — | — |
Q2 2022 | May 18, 2022 | — | $0.75 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-0.81 | — | — |
Q4 2021 | Nov 10, 2021 | — | $-1.04 | — | — |
Q3 2021 | Aug 23, 2021 | — | $-1.07 | — | — |
Q2 2021 | Apr 16, 2021 | — | $-0.88 | — | — |
Q4 2020 | Dec 31, 2020 | — | $0.10 | — | — |
Q4 2020 | Nov 11, 2020 | — | $2.08 | — | — |
Q3 2020 | Aug 12, 2020 | — | $-0.06 | — | — |
Latest News
Frequently Asked Questions about PAIOF
What is PAIOF's current stock price?
What is the analyst price target for PAIOF?
What sector is Paion AG in?
What is PAIOF's market cap?
Does PAIOF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PAIOF for comparison